Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

A trial of Sanofi’s new eczema drug has disappointed investors hoping for a replacement for its blockbuster Dupixent, sending the French pharma group’s shares down more than 9 per cent on Thursday.

LONDON (Reuters) -Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and ...

Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and ...

The most effective treatments for eczema accomplish three things: They calm inflammation, bring relief from itch and restore ...

Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding ...